Radiation Oncology Program

Download Radiation Oncology Program

HOSPITAL
University Hospitals Seidman Cancer Center

CO-DIRECTORS 
Mitchell Machtay, MD, Department Chair 216-983-4703
Rod Ellis, MD, Department Vice-Chair/Clinical Director 216-286-3903
David Mansur, MD, Vice Chair and Director of the UH Proton Therapy Center 216-286-3907

KEY CONTACTS 
Brenda Myers, RTT, MBA, Department Director 216-286-3955
Laura Krukowski, Manager 216-286-3976

APPOINTMENT LINE
Please call 216-844-3951. For the UH Proton Therapy Center, please call 216-286-7768.
For hospital transfers, please call 216-844-1111.

Conditions Treated

  • All malignant neoplasms
  • Several types of benign neoplasms, particularly those located in the brain and/or spine
  • Selected “benign” diseases of the brain, including arteriovenous malformations, trigeminal neuralgia and refractory essential tremor

Therapies

  • Proton beam radiation therapy
  • Gamma Knife® stereotactic radiosurgery (fixed frame brain treatment)
  • Linac-guided radiosurgery
  • Intraoperative radiation therapy
  • Full range of image-guided, intensity-modulated radiation therapy (IGRT/IMRT) procedures 
  • Full range of brachytherapy procedures (high-dose rate or low-dose rate)
  • Highly complex gynecologic and genitourinary brachytherapy, including multiparametric MRI image guidance
  • Re-irradiation for selected patients who have already received radiation to the same area

Distinguishing Features

  • 2,000 patients treated with radiosurgery since 2008
  • First Proton Therapy Center in Ohio, located adjacent to UH Rainbow Babies & Children’s Hospital and UH Seidman Cancer Center, fostering seamless, multidisciplinary care
  • Subspecialist radiation oncologists nationally recognized for their expertise in organ/disease site, including CNS/brain, lung/thoracic, breast, genitourinary/gynecologic, gastrointestinal and hematologic/pediatric
  • Advanced techniques for cardiac-sparing radiation therapy for patients with breast cancer and other thoracic neoplasms (lung, thymus, esophagus, lymphoma)
  • Extensive clinical trials, including leadership in national NCI-sponsored protocols (RTOG/NRG) and UH investigator-initiated in-house, early-phase trials
  • Among the top-accruing clinical trials centers in the nation